微信关注
China
Total item
Cart Subtotal
￥ 0.00 “AZ 960”的搜索结果
36 个项目
每页
-
Saracatinib (AZD0530)
Catalog No. A10108 Src/Abl 抑制剂Saracatinib (AZD0530)是一种高选择性，双特异性Src/Abl激酶抑制剂，对c-Src和Abl激酶的IC50分别为2.7和30 nM。 了解更多 -
AZD8931 (Sapitinib)
Catalog No. A10116 pan-EGFR/pan-erbB 抑制剂AZD8931 (Sapitinib)是ErbB1，ErbB2和ErbB3受体信号传导的等效抑制剂。 了解更多 -
Cediranib (AZD2171)
Catalog No. A10185 VEGFR 抑制剂Cediranib (AZD2171)是一种高效的VEGFR(KDR)抑制剂，此外对c-Kit和PDGFRβ也具有相似的抑制活性，对VEGFR的选择性比PDGFR-α，CSF-1R和Flt3分别高36倍，110倍 和1000倍以上。 了解更多 -
Pazopanib HCl (GW786034)
Catalog No. A10699 VEGFR/PDGFR/FGFR 抑制剂Pazopanib HCl (GW786034)是VEGFR-1，VEGFR-2，VEGFR-3，PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂，可阻止肿瘤生长并抑制血管生成。 了解更多 -
BAY 61-3606
Catalog No. A11320 Syk 抑制剂BAY 61-3606是一种细胞可渗透的咪唑并嘧啶化合物，可作为Syk酪氨酸激酶活性的有效，ATP竞争性，可逆和高度选择性抑制剂，而对Btk，Fyn，Itk，Lyn和Src无抑制作用。 了解更多 -
Pazopanib (GW-786034)
Catalog No. A11518 VEGFR 抑制剂Pazopanib (GW-786034)是VEGFR-1，VEGFR-2，VEGFR-3，PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂，可阻止肿瘤生长并抑制血管生成。 了解更多 -
AZD-9291 (Osimertinib)
Catalog No. A13681 EGFR 抑制剂AZD-9291 (Osimertinib)是第三代EGFR抑制剂，在临床前研究中显示出希望，并为已对现有EGFR抑制剂产生耐药性的晚期肺癌患者提供了希望。 了解更多 -
AZD3759
Catalog No. A15551 -
EGF816 (Nazartinib)
Catalog No. A14416 -
GSK1278863 (Daprodustat)
Catalog No. A12671 -
Derazantinib (ARQ-087)
Catalog No. A16825 FGFR 抑制剂Derazantinib (ARQ-087)是成纤维细胞生长因子受体（FGFR）的口服生物利用抑制剂，对于FGFR2的IC50值为1.8 nM，对于FGFR1和3的IC50值为4.5 nM，对FGFR4的效力较低（IC50 = 34 nM）。它还抑制RET，DDR2，PDGFRβ，VEGFR和KIT。 了解更多 -
Lazertinib (YH25448,GNS-1480)
Catalog No. A16827 EGFR 抑制剂Lazertinib (YH25448,GNS-1480)是一种有效的，高度突变选择性和不可逆的EGFR-TKI，对于Del19/T790M，L858R/T790M，Del19，Del19，IC50值分别为1.7 nM，2 nM，5 nM，20.6 nM和76 nM。L85R和野生型EGFR分别显示出更高的IC50值，即抗药性ErbB2和ErbB4。 了解更多 -
Poseltinib (HM71224, LY3337641)
Catalog No. A19450 BTK inhibitorPoseltinib, an orally active, selective and irreversible Bruton??s tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. 了解更多 -
CHMFL-ABL-121
Catalog No. A19079 ABL2 inhibitorCHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively. 了解更多 -
Mutated EGFR-IN-2
Catalog No. A18565 EGFR 抑制剂Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=??1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. 了解更多 -
CHMFL-ABL-039
Catalog No. A13182 BCR-ABL inhibitorCHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia. 了解更多 -
CHMFL-BTK-01
Catalog No. A12538 BTK inhibitorCHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. 了解更多 -
CHMFL-EGFR-202
Catalog No. A12524 EGFR inhibitorCHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. 了解更多 -
CHMFL-ABL/KIT-155
Catalog No. A12421 ABL/c-KIT dual kinase inhibitorCHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. 了解更多 -
Nazartinib mesylate
Catalog No. A21741 covalent mutant-selective EGFR inhibitorNazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. 了解更多 -
Nazartinib S-enantiomer
Catalog No. A21747 EGFR inhibitorNazartinib S-enantiomer (EGF816 S-enantiomer) is the less active S-enantiomer of Nazartinib. Nazartinib (EGF816) is an EGFR inhibitor. 了解更多 -
Cediranib maleate
Catalog No. A21857 VEGFR inhibitorCediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. 了解更多 -
Vatalanib free base
Catalog No. A21871 VEGFR2/KDR inhibitorVatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM. 了解更多 -
BCR-ABL-IN-2
Catalog No. A21043 inhibitor of BCR-ABL1 tyrosine kinaseBCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. 了解更多
36 个项目
每页
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
FILTER BY:
购物选项
- 分类
- 靶点
-
- CSF1R (1)
- EGFR (4)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (1)
- EGFR T790M (3)
- EGFR wild type (1)
- ErbB4 (1)
- FGFR (1)
- FGFR1 (1)
- FGFR2 (1)
- FGFR3 (1)
- FGFR4 (1)
- Kit (1)
- PDGFRα (1)
- PDGFRβ (1)
- VEGFR1 (FLT1) (1)
- VEGFR2 (FLK1) (1)
- VEGFR3 (FLT4) (1)
ADOOQ 产品质量保证
We promise all products to perform as described.